Oxybutynin
Prescription ·Exploratory record · not publication-reviewed ·Updated July 13, 2026
Oxybutynin is an antimuscarinic agent used for the treatment of overactive bladder (OAB) symptoms including urge urinary incontinence, urgency, and frequency. It is one of the oldest and most studied medications for OAB. Available in immediate-release, extended-release, transdermal patch, and topical gel formulations; extended-release and transdermal forms have improved tolerability compared to immediate-release.
Exploratory record, not a reviewed medical publication.
See the editorial and medical-review policies for the publication gate.
This generated database record has not completed a claim-level review by a qualified human medical reviewer. Bibliography links and evidence labels are not approval. The page remains available for reference and is excluded from search indexing.
What the research says.
A quick, data-only summary. The full evidence, dosing, and sources are below.
Oxybutynin is an antimuscarinic agent used for the treatment of overactive bladder (OAB) symptoms including urge urinary incontinence, urgency, and frequency. NutriStack rates the supporting evidence as strong. Common adult dosing is 5 mg two to three times daily (immediate-release); 5-10 mg once daily (extended-release); 3.9 mg/day transdermal patch (applied twice weekly) (as prescribed by your physician), though a prescriber sets the actual dose. This profile indexes 10 sources.
The bottom line
Evidence rating strong. Most-documented uses: reduces episodes of urge incontinence, decreases urinary urgency and frequency, multiple formulations for individualized therapy. 10 sources indexed (2001–2023), with 0 interaction records on file.
How it works, mechanistically.
Core mechanism
Exerts direct antispasmodic effects on smooth muscle and inhibits the muscarinic action of acetylcholine on bladder smooth muscle (detrusor muscle). Specifically blocks M1 and M3 muscarinic receptors on the detrusor, reducing involuntary bladder contractions that cause urgency and incontinence. Also has local anesthetic and calcium channel blocking properties at higher concentrations.
Dosing & protocol.
Oral bioavailability ~6% due to extensive first-pass hepatic metabolism to active metabolite N-desethyloxybutynin (which causes most anticholinergic side effects). Extended-release and transdermal formulations bypass first-pass metabolism, producing lower N-DEO levels.
Full safety detail.
Side effects
- Dry mouth (most common)
- Constipation
- Blurred vision
- Somnolence and dizziness
- Cognitive impairment (especially in elderly)
- Urinary retention
- Heat intolerance (decreased sweating)
- Application site reactions (transdermal)
Sources, by evidence tier.
Numbered references. Citations throughout the page link here.
Meta-analyses & systematic reviews
3- 1Safety and efficacy of oxybutynin in patients with hyperhidrosis: systematic review and meta-analysis of randomized controlled trialsPMIDEl-Samahy M, Mouffokes A, Badawy MM et al. · Archives of dermatological research · 2023
El-Samahy M, Mouffokes A, Badawy MM et al.. Safety and efficacy of oxybutynin in patients with hyperhidrosis: systematic review and meta-analysis of randomized controlled trials. Archives of dermatological research. 2023
- 2Intravesical oxybutynin therapy for patients with neurogenic detrusor overactivity: a systematic review and meta-analysisPMIDShen SH, Jia X, Peng L et al. · International urology and nephrology · 2022
Shen SH, Jia X, Peng L et al.. Intravesical oxybutynin therapy for patients with neurogenic detrusor overactivity: a systematic review and meta-analysis. International urology and nephrology. 2022
- 3Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: a meta-analysisPMIDHarvey MA, Baker K, Wells GA · American journal of obstetrics and gynecology · 2001
Harvey MA, Baker K, Wells GA. Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: a meta-analysis. American journal of obstetrics and gynecology. 2001
Randomized controlled trials
2- 4One Month Dosing of Atomoxetine plus Oxybutynin in Obstructive Sleep Apnea: A Randomized, Placebo-controlled TrialPMIDAishah A, Loffler KA, Toson B et al. · Annals of the American Thoracic Society · 2023
Aishah A, Loffler KA, Toson B et al.. One Month Dosing of Atomoxetine plus Oxybutynin in Obstructive Sleep Apnea: A Randomized, Placebo-controlled Trial. Annals of the American Thoracic Society. 2023
- 5Effect of oxybutynin and reboxetine on obstructive sleep apnea: a randomized, placebo-controlled, double-blind, crossover trialPMIDBerger M, Solelhac G, Marchi NA et al. · Sleep · 2023
Berger M, Solelhac G, Marchi NA et al.. Effect of oxybutynin and reboxetine on obstructive sleep apnea: a randomized, placebo-controlled, double-blind, crossover trial. Sleep. 2023
Reference material
5- 6Chapple CR et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol. 2005;48(3):464-470.Source linkedPMID
- 7Dmochowski RR et al. Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials. World J Urol. 2005;23(4):263-270.Source linkedPMID
- 8Coupland CAC et al. Anticholinergic drug exposure and the risk of dementia: a nested case-control study. JAMA Intern Med. 2019;179(8):1084-1093.Source linkedPMID
- 9Taranto-Montemurro L, Messineo L, Sands SA et al.. The Combination of Atomoxetine and Oxybutynin Greatly Reduces Obstructive Sleep Apnea Severity. A Randomized, Placebo-controlled, Double-Blind Crossover Trial. American journal of respiratory and critical care medicine. 2019Source linkedPMID
- 10Dwyer J, Tafuri SM, LaGrange CA. Oxybutynin. 2026Source linkedPMID
Common questions.
Quick answers about Oxybutynin, drawn from the data on this page.
What is Oxybutynin?
Oxybutynin is an antimuscarinic agent used for the treatment of overactive bladder (OAB) symptoms including urge urinary incontinence, urgency, and frequency. It is one of the oldest and most studied medications for OAB. Available in immediate-release, extended-release, transdermal patch, and topical gel formulations; extended-release and transdermal forms have improved tolerability compared to immediate-release.
What is Oxybutynin used for?
Commonly cited benefits of Oxybutynin include: Reduces episodes of urge incontinence; Decreases urinary urgency and frequency; Multiple formulations for individualized therapy; Transdermal formulation reduces anticholinergic side effects. NutriStack rates the overall evidence as strong.
What is a typical dose of Oxybutynin?
A typical adult dose of Oxybutynin is 5 mg two to three times daily (immediate-release); 5-10 mg once daily (extended-release); 3.9 mg/day transdermal patch (applied twice weekly) (as prescribed by your physician). The commonly recommended form is Extended-release tablets (Ditropan XL) or transdermal patch/gel preferred to minimize dry mouth and other anticholinergic effects. These are general ranges, not personalized advice; confirm the right dose with a clinician.
What are the side effects of Oxybutynin?
Reported side effects include dry mouth (most common), constipation, blurred vision, somnolence and dizziness, cognitive impairment (especially in elderly), urinary retention. This is educational information; check with a healthcare professional before use.
How strong is the evidence for Oxybutynin?
NutriStack rates this as Strong, meaning multiple high-quality meta-analyses or systematic reviews converge on the same finding. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.
Use this with your stack
Oxybutynin in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.